Chordate Medical at IHC 2023: ”Great Interest in Ozilia®”

Chordate Medical's booth was well-attended during the International Headache Congress in Seoul, which took place from September 14th to 17th, and CEO Anders Weilandt and Clinical Research & Medical Director Jan Hermansson were busy discussing Ozilia® Migraine (formerly K.O.S).

“Thanks to Dr. Hoffmann's poster and presentation, as well as other presenters mentioning Ozilia® Migraine as an alternative in their talks – combined with our marketing effort as a sponsor of the congress, the traffic to our booth was very satisfying," says Anders Weilandt, CEO of Chordate.

IHC 2023 marked the launch of Ozilia® Migraine, the new brand for Chordate Medical's migraine treatment. Ozilia® replaces K.O.S as the brand in all markets where Chordate is active.

“During the congress, we received clear confirmation that Ozilia® Migraine is seen as a relevant drug-free alternative, and awareness of our treatment technique was effectively disseminated among influential congress participants. We were able to establish valuable new contacts in both Europe and the USA that have the potential to lead to interesting developments of our business venture," says Anders Weilandt.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact